Table 1.
Number of dossiers used in the study stratified by Health Technology Assessment organization and disease
| Organization | Total | Cancer | Hepatitis C |
|---|---|---|---|
| AETSA | 12 | 5 | 7a |
| AIFA | 8 | 8 | 0 |
| CADTH/pCODR | 28 | 21 | 7 |
| C2H | 7 | 2 | 5 |
| HAS | 29 | 22 | 7 |
| IQWiG | 29 | 23 | 6 |
| NICE | 25 | 23 | 2 |
| PBAC | 51 | 43 | 8b |
| Total | 189 | 147 | 42 |
aDaklinza, Exviera, Harvoni, Holkira Pak, Olysio, Sovaldi, Viekirax are evaluated in one dossier for AETSA
bDaklinza and Sunvepra are evaluated in one dossier for PBAC
AETSA Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, AIFA Agenzia Italiana del Farmaco, C2H Center for Outcomes Research and Economic Evaluation for Health, CADTH Canadian Agency for Drugs and Technologies in Health, HAS Haute Autorité de Santé, IQWiG Institute for Quality and Efficiency in Healthcare, NICE National Institute for Health and Care Excellence, PBAC Pharmaceutical Benefits Advisory Committee, pCODR pan-Canadian Oncology Drug Review